The Debiopharm Group, headquartered in Lausanne (Switzerland) has announced its Alisporovir brand will under-go preclinical trials to treat Duchenne Muscular Dystrophy (DMD) in collaboration with Solid Biosciences, a Cambridge (MA) biotech dedicated to research of DMD.
The Debiopharm Group has been around for over 40 years, with 4 international subsidiary companies within the Swiss-based group. Solid Biosciences on the other-hand is US based, specialising in developing drugs, therapies and med-tech for the specific treatment of DMD – a degenerative disease caused by X-linked form of skeletal and cardiac muscle dystrophy due to the absence of the structural protein dystrophin.
Alisporovir, initially being licensed out to Novartis, was actually cancelled in January after the pharma giant decided against the pursuit of Hepatitis-C research as a strategic focus in their portfolio. By partnering up with Solid Biosciences – the experts in the research of DMD – Debiopharm will instead use Alisporovir to develop a potential DMD treatment. Having been tested in over 2000 patients during Novartis’ HVC research,